42 citations
,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
18 citations
,
February 2021 in “Dermatologic therapy” Public interest in skin issues changed during COVID-19, with more focus on dry skin, hair problems, and hand eczema.
14 citations
,
June 2020 in “Journal of the American Academy of Dermatology” Global collaboration in dermatology improved data sharing and patient care during COVID-19.
9 citations
,
July 2021 in “Essays in Biochemistry” Sex hormones may influence COVID-19 severity, with males at higher risk, and certain hormone therapies could potentially treat the virus.
8 citations
,
July 2023 in “Frontiers in Pharmacology” Cepharanthine shows promise as a COVID-19 treatment.
6 citations
,
January 2024 in “Cancers” Antiandrogens don't help with COVID-19 and aren't recommended.
1 citations
,
October 2025 in “Biology of Sex Differences” Gender and social factors, not just biology, affect COVID-19 death rates.
6 citations
,
December 2022 in “Journal of Infection” The ACE1 gene variant doesn't affect long-COVID symptoms.
February 2024 in “PubMed” More people experience hair loss after recovering from COVID-19 in hospitals than in outpatient settings.
19 citations
,
December 2021 in “Cureus” Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
2 citations
,
October 2020 in “Annals of Oncology” Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.
2 citations
,
October 2020 in “Journal of Pharmacy And Bioallied Sciences” Hydroxychloroquine and chloroquine are not recommended for COVID-19 treatment due to insufficient evidence and safety concerns.
4 citations
,
November 2023 in “PLoS ONE” Interest in long-COVID symptoms in Japan increased with COVID-19 case peaks, especially for hair loss, cough, smell/taste issues, and headache.
52 citations
,
March 2022 in “Biology of Sex Differences” Females have stronger immune responses to COVID-19 than males, leading to better outcomes.
16 citations
,
March 2022 in “Journal of Infection” Booster doses of Covaxin improve protection against the Omicron variant.
6 citations
,
March 2022 in “Frontiers in drug discovery” Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.
170 citations
,
September 2020 in “Viruses” Drug repositioning offers a cost-effective, lower-risk way to treat diseases and pandemics like COVID-19.
5 citations
,
December 2021 in “Journal of Cosmetic Dermatology” QR678 Neo® hair growth treatment is effective for hair loss caused by Covid-19.
17 citations
,
May 2022 in “Frontiers in Immunology” Reprogramming macrophages to resolve inflammation can help reduce severe COVID-19 complications.
8 citations
,
August 2022 in “Microorganisms” A standardized drug development platform is essential for efficient and effective drug repurposing, especially during pandemics.
1 citations
,
March 2022 in “Irish Journal of Medical Science” Men with androgenetic alopecia and hypertension may experience more severe COVID-19.
September 2025 in “International Journal of Emergency Medicine” More skin issues appeared in the emergency department during COVID-19, highlighting the need for better dermatology training and resources.
22 citations
,
September 2021 in “Journal of Personalized Medicine” The pandemic worsened physical and mental challenges for women with PCOS.
14 citations
,
April 2022 in “Molecules” Pulmonary delivery of cepharanthine significantly improves its effectiveness and shows promise for treating lung fibrosis linked to COVID-19.
2 citations
,
October 2022 in “Current Dermatology Reports” People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.
The study concludes that long COVID recovery involves time, various treatments, and a strong patient-provider relationship.
April 2021 in “European journal of medical and health sciences” The pandemic stress may have increased alopecia cases in Bangladesh.
32 citations
,
March 2021 in “Journal of cosmetic dermatology (Print)” COVID-19 infection may trigger alopecia areata in some patients.
22 citations
,
October 2021 in “Dermatologic Therapy” COVID-19 may cause temporary hair loss in some people.
4 citations
,
June 2022 in “Indian Dermatology Online Journal” COVID-19 may cause temporary hair loss due to direct damage to hair follicles, but it usually gets better on its own.